The estimated Net Worth of Inc. Medytox is at least $85 million dollars as of 16 October 2023. Inc Medytox owns over 1,690,663 units of Evolus Inc stock worth over $51,632,848 and over the last 3 years Inc sold EOLS stock worth over $33,399,789.
Sign up
Inc Medytox EOLS stock SEC Form 4 insiders trading
Inc has made over 15 trades of the Evolus Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Inc sold 1,690,663 units of EOLS stock worth $12,679,973 on 16 October 2023.
The largest trade Inc's ever made was selling 2,187,511 units of Evolus Inc stock on 7 February 2023 worth over $18,593,844. On average, Inc trades about 321,358 units every 53 days since 2021. As of 16 October 2023 Inc still owns at least 3,381,326 units of Evolus Inc stock.
You can see the complete history of Inc Medytox stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Inc Medytox's mailing address?
Inc's mailing address filed with the SEC is 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGIU-SI, M5, 28126.
Insiders trading at Evolus Inc
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox et 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
What does Evolus Inc do?
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
What does Evolus Inc's logo look like?
Complete history of Inc Medytox stock trades at Evolus Inc
Evolus Inc executives and stock owners
Evolus Inc executives and other stock owners filed with the SEC include:
-
Michael Jafar,
Chief Commercial Officer -
David Moatazedi,
President, Chief Executive Officer, Director -
Rui Avelar,
Chief Medical Officer, Head of Research & Development -
David Moatazedi,
Pres, CEO & Director -
Lauren Silvernail,
Chief Financial Officer, Executive Vice President - Corporate Development -
Lauren P. Silvernail,
CFO & Exec. VP of Corp. Devel. -
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
Chief Medical Officer and Head of R&D -
Karah Parschauer,
Independent Director -
Peter Farrell,
Independent Director -
Vikram Malik,
Chairman of the Board -
David Gill,
Independent Director -
Robert Hayman,
Independent Director -
Simone Blank,
Director -
Tram Bui,
IR Contact Officer -
Jeff Plumer,
General Counsel -
Jessica Novak,
Sr. VP of HR -
Crystal Muilenburg,
Chief Marketing Officer -
Kurt Knab,
VP of Sales -
Jeffrey J. Plumer,
Gen. Counsel -
David K. Erickson,
VP of Investor Relations -
Biopharma, Inc. Aeon,
-
Sandra Beaver,
Chief Financial Officer -
Crystal Muilenburg,
Chief Marketing Officer -
Albert G Iii White,
Director -
Kristine Romine,
Director -
Bosun Hau,
Director -
1 Llc Alphaeon,
-
Brady Stewart,
Director -
Tomoko Yamagishi Dressler,
Chief Marketing Officer -
Inc. Medytox,